Bank of New York Mellon’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-325,943
| Closed | -$12.9M | – | 4319 |
|
|
2024
Q1 | $12.9M | Buy |
325,943
+223,591
| +218% | +$6.6M | ﹤0.01% | 1832 |
|
|
2023
Q4 | $1.95M | Buy |
102,352
+9,629
| +10% | +$134K | ﹤0.01% | 2847 |
|
|
2023
Q3 | $1.06M | Buy |
92,723
+1,216
| +1% | +$15K | ﹤0.01% | 3114 |
|
|
2023
Q2 | $941K | Buy |
91,507
+19,701
| +27% | +$178K | ﹤0.01% | 3224 |
|
|
2023
Q1 | $554K | Sell |
71,806
-11,785
| -14% | -$93.9K | ﹤0.01% | 3443 |
|
|
2022
Q4 | $614K | Buy |
83,591
+19,111
| +30% | +$122K | ﹤0.01% | 3450 |
|
|
2022
Q3 | $464K | Buy |
64,480
+5,926
| +10% | +$48.8K | ﹤0.01% | 3604 |
|
|
2022
Q2 | $499K | Buy |
58,554
+9,399
| +19% | +$81K | ﹤0.01% | 3587 |
|
|
2022
Q1 | $441K | Sell |
49,155
-2,590
| -5% | -$22.4K | ﹤0.01% | 3789 |
|
|
2021
Q4 | $716K | Buy |
51,745
+1,207
| +2% | +$15K | ﹤0.01% | 3577 |
|
|
2021
Q3 | $539K | Buy |
50,538
+8,676
| +21% | +$79.9K | ﹤0.01% | 3770 |
|
|
2021
Q2 | $377K | Buy |
41,862
+19,178
| +85% | +$208K | ﹤0.01% | 3898 |
|
|
2021
Q1 | $240K | Sell |
22,684
-742
| -3% | -$9.25K | ﹤0.01% | 3991 |
|
|
2020
Q4 | $295K | Buy |
23,426
+12,088
| +107% | +$119K | ﹤0.01% | 3837 |
|
|
2020
Q3 | $100K | Buy |
+11,338
| New | +$104K | ﹤0.01% | 3955 |
|
|
2016
Q4 | – | Sell |
-4,124
| Closed | -$134K | – | 4320 |
|
|
2016
Q3 | $134K | Buy |
4,124
+298
| +8% | +$7.26K | ﹤0.01% | 3979 |
|
|
2016
Q2 | $70K | Sell |
3,826
-1,954
| -34% | -$34.7K | ﹤0.01% | 4124 |
|
|
2016
Q1 | $97K | Buy |
5,780
+2,393
| +71% | +$47.9K | ﹤0.01% | 3968 |
|
|
2015
Q4 | $105K | Buy |
3,387
+364
| +12% | +$12.4K | ﹤0.01% | 4048 |
|
|
2015
Q3 | $157K | Buy |
+3,023
| New | +$199K | ﹤0.01% | 3987 |
|
Bank of New York Mellon's ALPN Position: Q2 2024 in Review
Bank of New York Mellon sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 325,943 shares — an estimated $12.9M sold.
Bank of New York Mellon first reported a position in ALPN in Q3 2015 and held it in 20 quarters. The position peaked at $12.9M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Bank of New York Mellon reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 325,943 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $12.9M.
- Bank of New York Mellon first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 20 quarters.
- Bank of New York Mellon's Alpine Immune Sciences Inc position peaked at $12.9M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.